Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B8299

Sigma-Aldrich

N-Butyldeoxynojirimycin

film (dried in situ), ≥98% (TLC)

Synonym(s):

Miglustat, NB-DNJ

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H21NO4
CAS Number:
72599-27-0
Molecular Weight:
219.28
MDL number:
MFCD00272581
UNSPSC Code:
12352200
PubChem Substance ID:
24892070
NACRES:
NA.32

product name

N-Butyldeoxynojirimycin, film (dried in situ)

Assay

≥98% (TLC)

Quality Level

200

form

film (dried in situ)

solubility

water: 9.80-10.20 mg/mL, clear, colorless

storage temp.

2-8°C

SMILES string

CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

InChI

1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1

InChI key

UQRORFVVSGFNRO-UTINFBMNSA-N

Gene Information

human ... UGCG(7357)

Related Categories

General description

N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.

Application

N-Butyldeoxynojirimycin has been used:
  • in the inhibition of glycolipid synthesis in neuroblastoma cells
  • in the inhibition the ceramide-specific glycosyltransferase in hepatocytes
  • in the inhibition of β-glucosidase (GBA2) using fluorescence- activity assay in human embryonic kidney (HEK293) cells.

Biochem/physiol Actions

N-Butyldeoxynojirimycin is an inhibitor of glucosyltransferase and α-glucosidases. N-Butyldeoxynojirimycin, also known as misglustat, reduces glycolipid levels by substrate reduction therapy (SRT) and is effectively used for the treatment of glycosphingolipid lysosomal storage disorder, Gaucher disease.
α-glucosidase Inhibitor

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Olivier Bonnot et al.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 20(4), 310-319 (2017-09-16)
Objectives: Niemann-Pick disease type C (NP-C) is a rare inherited neurovisceral disease that should be recognised by psychiatrists as a possible underlying cause of psychiatric abnormalities. This study describes NP-C patients who had psychiatric manifestations at enrolment in the international
Aizeddin Mhanni et al.
Diagnostics (Basel, Switzerland), 10(2) (2020-01-30)
Intraocular lesions have been infrequently reported in patients with Gaucher disease type 3 (GD3). We previously reported siblings with GD3 who responded well to the combination of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Here we report progressive
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
Platt FM et al.
The Journal of Biological Chemistry, 269(11), 8362-8365 (1994)
How adhesion/growth-regulatory galectins-1 and-3 attain cell specificity: case study defining their target on neuroblastoma cells (SK-N-MC) and marked affinity regulation by affecting microdomain organization of the membrane
Kopitz J, et al.
IUBMB Life, 62(8), 624-628 (2010)
Imiglucerase in the treatment of Gaucher disease: a history and perspective
Deegan PB and Cox TM
Drug design, development and therapy, 6, 81-81 (2012)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service